Mainstay is a medical device company focused on commercializing an innovative implantable Restorative Neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands.
Mainstay Medical does not regularly monitor, screen, or check this account. Any comments, questions, or posts left by visitors, will not be reviewed timely or receive a response. If you have any questions about Mainstay or the ReActiv8 product, please visit www.mainstaymedical.com.
Mainstay Medical does not regularly monitor, screen, or check this account. Any comments, questions, or posts left by visitors, will not be reviewed timely or receive a response. If you have any questions about Mainstay or the ReActiv8 product, please visit www.mainstaymedical.com.
Location: Ireland
Employees: 51-200
Total raised: $125M
Founded date: 2008
Investors 2
| Date | Name | Website |
| - | KCK Medtec... | kckmedtech... |
| 29.01.2022 | IPF Partne... | ipfpartner... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.02.2024 | - | $125M | - |
Mentions in press and media 16
| Date | Title | Description |
| 10.07.2026 | Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield | Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic lo... |
| 10.07.2026 | Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8® | ReActiv8® Restorative NeurostimulationTM demonstrated statistically significant and clinically meaningful superiority vs. standard of care in all primary and secondary measures of disability, pain and quality of life Safety profile consiste... |
| 29.01.2025 | From The Philippines To Argentina, These Four Countries Saw Startup Funding Rise | 1 Shares Email Facebook Twitter LinkedIn Although global venture funding rose overall in 2024, it wasn’t a particularly strong year for emerging economies. Gains largely came from AI megadeals for companies in Silicon Valley and other big t... |
| 20.03.2024 | Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up | Groundbreaking ReActiv8-B study supports the long-term efficacy, safety and durability of ReActiv8® Restorative NeurostimulationTM for the treatment of intractable Chronic Low Back Pain Mainstay Medical Holdings plc today announced the p... |
| 13.03.2024 | Mainstay Medical Announces Publication of Clinical Results Comparing Older Patients and Younger Patients | Efficacy of ReActiv8® Restorative Neurostimulation™ shows no statistically or clinically meaningful differences between older and younger patient populations. Mainstay Medical Holdings plc today announced the publication of a pooled anal... |
| 28.02.2024 | Mainstay Medical Secures $125M Funding for Revolutionary Back Pain Treatment | Dublin-based Mainstay Medical Holdings recently announced a major equity financing deal, raising a whopping $125 million to support the commercial growth of their innovative implantable Restorative Neurostimulation system, ReActiv8. Led by ... |
| 27.02.2024 | Mainstay Medical Announces US$125M Equity Financing Transaction | Mainstay Medical Holdings, a Dublin, Ireland-based medical device company, announced an equity financing in which it received gross proceeds of US$125M. The financing was led by Gilde Healthcare and Viking Global Investors. Existing investo... |
| 27.02.2024 | Dublin-based Mainstay Medical Holdings raises USD 125 million in funding | Dublin, Ireland-based medical device company, Mainstay Medical Holdings raised an equity financing in which it received gross proceeds of USD 125 million. The company announced the investment on February 26, 2024. Gilde Healthcare and Vikin... |
| 26.02.2024 | Mainstay Medical Announces US$125 Million Equity Financing Transaction | Funding to accelerate commercial growth and expand clinical and health economic evidence for ReActiv8® Restorative NeuromodulationTM System Mainstay Medical Holdings plc today announced an equity financing in which it will receive gross ... |
| 13.02.2024 | Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation SystemTM | U.S. patients implanted with ReActiv8 now eligible for full-body MRI scans Mainstay Medical Holdings plc today announced that the U.S. Food and Drug Administration (FDA) has approved full-body MRI conditional labeling for the ReActiv8® R... |
Show more